MindBio Therapeutics (XCNQ:MBIO) EPS (Basic) : C$-0.02 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics EPS (Basic)?

MindBio Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was C$0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.02.

MindBio Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was C$0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.02.

MindBio Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was C$0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.02.

During the past 12 months, MindBio Therapeutics's average EPS without NRIGrowth Rate was -800.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

MindBio Therapeutics EPS (Basic) Historical Data

The historical data trend for MindBio Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics EPS (Basic) Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

EPS (Basic)

-0.05

-0.04

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial					-	-0.02	-	-	-

MindBio Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

MindBio Therapeutics's Basic EPS for the fiscal year that ended in Jun. 2023 is calculated as

Basic EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.823	-	0)	/	110.135
	=	-0.03

MindBio Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.068	-	0)	/	133.047
	=	0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02

MindBio Therapeutics (XCNQ:MBIO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MindBio Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.